Testosterone breakthrough during ADT intensification linked to worse outcomes in LATITUDE, not ARASENS
Retrospective · BJU Int · 2026-10-06. Number 4 in the UrologyWatch Top 5 for October 6, 2026.
Post hoc landmark analyses of two phase 3 mHSPC trials found testosterone breakthrough above 35 ng/dL was associated with worse overall survival in LATITUDE (HR 1.49) but not significantly in ARASENS (HR 1.18 for OS, HR 0.86 for time to CRPC).
Why it matters: Raises the question of whether monitoring and correcting testosterone breakthrough during ADT intensification could improve outcomes, though trial-specific differences warrant caution.
Source: BJU Int · PubMed 42833883 · DOI 10.1111/bju.70474
Loading today's edition…